Nanjing Leads Biolabs Doses First Patient in Lupus Erythematosus Drug Trial

MT Newswires Live10-30

Nanjing Leads Biolabs (HKG:9887) dosed the first patient with systemic lupus erythematosus in part B of a phase I trial of LBL-047.

This is the first administration of the drug to patients with an autoimmune disease, a Friday bourse filing showed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment